No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 19 of the 31 quarters in the window, leaving 12 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 109.7x · 10Y median 3580.0x · 30th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 32
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T18:20:22.759Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Allogene Therapeutics, Inc. (ALLO) stock was $1.48 as of Oct 6, 2026, 2:20 PM EDT, down 1.67% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +12.7% · 3-year avg -21.9%/yr · 5-year avg -42.7%/yr
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers.
Biotechnology · South San Francisco, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.15
Revenue Est.
$2500.00
Last Quarter Results
EPS
$-0.13
vs Estimate
$-0.15
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ALLO | $509.10M | $1.48 | -1.67% | +12.72% | -42.72% | N/A | N/A |
| 2CBIO | $509.99M | $13.73 | -1.51% | +18.84% | -24.40% | -22.94% | vs ALLO |
| 3MASS | $510.55M | $12.44 | -2.78% | +40.89% | -17.66% | N/A | vs ALLO |
| 4TCMD | $502.33M | $22.27 | -0.89% | +47.55% | -11.73% | +1.68% | vs ALLO |
| 5ALT | $520.12M | $2.67 | +0.17% | -31.59% | -25.30% | N/A | vs ALLO |
| 6OCS | $496.43M | $8.68 | +1.44% | -51.11% | -2.41% | N/A | vs ALLO |
forward FY estimate
N/A
$4.64M
vs Estimate
$2500.00
Consensus Rating
Based on 9 analysts
Average Price Target
$9.00
+510.2% upside
Low
$4.00
Current
$1.48
High
$14.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.17 | $-0.15 | $-0.10 | 6 |
| Quarter ending Dec 2026 | $-0.16 | $-0.15 | $-0.13 | 6 |
| Quarter ending Mar 2027 | $-0.15 | $-0.15 | $-0.15 | 2 |
| Quarter ending Jun 2027 | $-0.16 | $-0.16 | $-0.16 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.64 | $-0.60 | $-0.55 | 8 |
| FY 2027 | $-0.69 | $-0.64 | $-0.56 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2500.00 | $2500.00 | $2500.00 | 10 |
| Quarter ending Dec 2026 | $2500.00 | $2500.00 | $2500.00 | 10 |
| Quarter ending Mar 2027 | $5000.00 | $5000.00 | $5000.00 | 9 |
| Quarter ending Jun 2027 | $5000.00 | $5000.00 | $5000.00 | 9 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $3.81M | $3.82M | $3.84M | 8 |
| FY 2027 | $13.37M | $13.43M | $13.49M | 7 |
